1 min read

ID: 723231

Short Link: https://gregory-ms.com/articles/723231/

Discovery Date: 19 July 2022, 18:00:09 UTC

Published Date: 2022-07-19 10:00:00

Source: PubMed

Link: https://pubmed.ncbi.nlm.nih.gov/35850304/?utm_source=Other&utm_medium=rss&utm_campaign=pubmed-2&utm_content=10guX6I3SqrbUeeLKSTD6FCRM44ewnrN2MKKTQLLPMHB4xNsZU&fc=20210216052009&ff=20220719140007&v=2.17.7

Manual Selection: true

Machine Learning Gaussian Naive Bayes Model: false

Abstract

Osteoporosis and multiple sclerosis are highly prevalent diseases with limited treatment options. In light of these unmet medical needs, novel therapeutic approaches are urgently sought. Previously, the activation of the transmembrane receptor Plexin-B1 by its ligand semaphorin 4D (Sema4D) has been shown to suppress bone formation and to promote neuroinflammation in mice. However, it is unclear whether inhibition of this receptor-ligand interaction by an anti-Plexin-B1 antibody could represent a…

Noun Phrases in Title

  • An antagonistic monoclonal anti-Plexin-B1 antibody
  • therapeutic effects
  • mouse models
  • postmenopausal osteoporosis
  • multiple sclerosis
This is an independent project that runs on the good will of volunteers

You can help by spreading the word or by donating what you can to pay for the server costs.